Tango Reports Phase 1/2 Pancreatic Cancer Study Results

The company reported an 82% objective response rate and a 9-month progression-free survival rate of 88% in patients with second- or third-line pancreatic cancer treated with vopimetostat plus daraxonrasib. Median progression-free survival has not been reached.